Compare BTQ & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTQ | SPRY |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | 35 | 159 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.4M | 788.5M |
| IPO Year | N/A | 2020 |
| Metric | BTQ | SPRY |
|---|---|---|
| Price | $3.68 | $7.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 5.3M | 1.9M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $2,332.99 | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.09 | $6.66 |
| 52 Week High | $16.00 | $18.63 |
| Indicator | BTQ | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 39.43 | 41.19 |
| Support Level | $2.33 | $7.41 |
| Resistance Level | $7.21 | $8.61 |
| Average True Range (ATR) | 0.59 | 0.57 |
| MACD | -0.25 | -0.16 |
| Stochastic Oscillator | 1.18 | 12.87 |
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. The company derives revenue from Software licensing. Geographically, the company has a presence in Canada, Taiwan, Australia, and the United States.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.